Allogene Therapeutics, Inc.2025财年第一财季实现净利润-59.73百万美元，同比增加8.11%

市场透视2025-05-19

5月19日，Allogene Therapeutics, Inc.（ALLO.US）公布财报，公告显示公司2025财年第一财季净利润为-59.73百万美元，同比增加8.11%；其中营业收入为0.00美元，每股基本收益为-0.28美元。从资产负债表来看，Allogene Therapeutics, Inc.（ALLO.US）总负债1.23亿美元，其中短期债务7.63百万美元，资产负债比为4.14，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2536594111?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-19 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536594111","market":"us","top_or_hot":-1,"title":"Allogene Therapeutics, Inc.2025财年第一财季实现净利润-59.73百万美元，同比增加8.11%","media":"市场透视","content":"<div>\n<p>5月19日，Allogene Therapeutics, Inc.（ALLO.US）公布财报，公告显示公司2025财年第一财季净利润为-59.73百万美元，同比增加8.11%；其中营业收入为0.00美元，每股基本收益为-0.28美元。从资产负债表来看，Allogene Therapeutics, Inc.（ALLO.US）总负债1.23亿美元，其中短期债务7.63百万美元，资产负债比为4.14，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000704a482f1d3&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allogene Therapeutics, Inc.2025财年第一财季实现净利润-59.73百万美元，同比增加8.11%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllogene Therapeutics, Inc.2025财年第一财季实现净利润-59.73百万美元，同比增加8.11%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-19 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000704a482f1d3&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月19日，Allogene Therapeutics, Inc.（ALLO.US）公布财报，公告显示公司2025财年第一财季净利润为-59.73百万美元，同比增加8.11%；其中营业收入为0.00美元，每股基本收益为-0.28美元。从资产负债表来看，Allogene Therapeutics, Inc.（ALLO.US）总负债1.23亿美元，其中短期债务7.63百万美元，资产负债比为4.14，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000704a482f1d3&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALLO","symbol_name":"Allogene Therapeutics Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000704a482f1d3&s=b","article_id":"2536594111","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000704a482f1d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536594111","pubTimestamp":1747584109,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"5月19日，Allogene Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-59.73百万美元，同比增加8.11%；其中营业收入为0.00美元，每股基本收益为-0.28美元。从资产负债表来看，Allogene Therapeutics, Inc.总负债1.23亿美元，其中短期债务7.63百万美元，资产负债比为4.14，流动比率为0.10。机构评级：截至2025年5月19日，当前有10家机构对Allogene Therapeutics, Inc.目标价做出预测，其中目标均价为8.20美元，其中最低目标价为3.00美元，最高目标价为14.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"ALLO":"Allogene Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"Allogene Therapeutics, Inc. achieved net profit of-US $59.73 million in the first fiscal quarter of fiscal year 2025, a year-on-year increase of 8.11%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":0.9,"LENZ":1},"content_text":"5月19日，Allogene Therapeutics, Inc.（ALLO.US）公布财报，公告显示公司2025财年第一财季净利润为-59.73百万美元，同比增加8.11%；其中营业收入为0.00美元，每股基本收益为-0.28美元。从资产负债表来看，Allogene Therapeutics, Inc.（ALLO.US）总负债1.23亿美元，其中短期债务7.63百万美元，资产负债比为4.14，流动比率为0.10。机构评级：截至2025年5月19日，当前有10家机构对Allogene Therapeutics, Inc.目标价做出预测，其中目标均价为8.20美元，其中最低目标价为3.00美元，最高目标价为14.00美元。公司简介：Allogene Therapeutics Inc 是一家临床阶段的生物技术公司，专门从事免疫肿瘤学，专注于开发用于癌症和自身免疫性疾病的基因工程同种异体 T 细胞产品。他们的产品线包括现成的 T 细胞候选细胞，旨在靶向自身免疫性疾病中的癌细胞或自身反应细胞。值得注意的是，他们来自健康捐献者的同种异体方法允许更广泛的患者资格和可扩展性。公司以重新定义 CAR T 疗法为愿景，专注于针对淋巴瘤、白血病、自身免疫性疾病和实体瘤的核心项目。来自合作和许可协议的收入支持他们的研发工作。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2536594111","isCrawlerRequest":true}